252 related articles for article (PubMed ID: 34287098)
1. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.
Wang HH; Liu CW; Li YC; Huang YC
Acta Derm Venereol; 2015 Nov; 95(8):928-32. PubMed ID: 25881672
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
Róbert L; Kovács A; Sárdy M; Fábián M
Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.
Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M
Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226
[TBL] [Abstract][Full Text] [Related]
6. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
Londhe PJ; Kalyanpad Y; Khopkar US
Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
[TBL] [Abstract][Full Text] [Related]
8. Durable remission of pemphigus with a fixed-dose rituximab protocol.
Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy in pemphigus: A long-term follow-up.
Loi C; Magnano M; Ravaioli GM; Sacchelli L; Patrizi A; Bardazzi F
Dermatol Ther; 2019 Jan; 32(1):e12763. PubMed ID: 30288877
[No Abstract] [Full Text] [Related]
10. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
Cho HH; Jin SP; Chung JH
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
[TBL] [Abstract][Full Text] [Related]
11. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
12. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
[TBL] [Abstract][Full Text] [Related]
13. A single cycle of rituximab for the treatment of severe pemphigus.
Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up.
Kim TH; Choi Y; Lee SE; Lim JM; Kim SC
J Dermatol; 2017 Jun; 44(6):615-620. PubMed ID: 28186358
[TBL] [Abstract][Full Text] [Related]
15. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.
Balighi K; Daneshpazhooh M; Akbari Z; Tavakolpour S; Azimi P; Azizpour A
J Dermatolog Treat; 2019 Jun; 30(4):346-349. PubMed ID: 30081690
[No Abstract] [Full Text] [Related]
16. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
17. Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients.
Louchez A; El Aarbaoui T; Weill A; Gaudin O; Jelti L; Belmondo T; Wolkenstein P; Ingen-Housz-Oro S
Ann Dermatol Venereol; 2024 Jun; 151(2):103264. PubMed ID: 38537431
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
[TBL] [Abstract][Full Text] [Related]
19. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
Reguiai Z; Tabary T; Maizières M; Bernard P
J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
[TBL] [Abstract][Full Text] [Related]
20. Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation?
Balighi K; Hatami P; Sheikh Aboli MJ; Daneshpazhooh M; Ghiasi M; Mahmoudi HR; Aryanian Z
Dermatol Ther; 2022 Feb; 35(2):e15249. PubMed ID: 34910350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
